-
公开(公告)号：US20180228899A1
公开(公告)日：2018-08-16
申请号：US15956099
申请日：2018-04-18
Applicant: Variation Biotechnologies Inc.
Inventor： Marc J. Kirchmeier , David E. Anderson
IPC: A61K47/14 , A61K47/28 , A61K39/00 , A61K39/12 , A61K39/165 , A61K39/20 , A61K39/295 , A61K39/395 , C12N7/00 , C07K16/32 , A61K47/24 , A61K9/127
Abstract: The present disclosure provides inter alia compositions that comprise therapeutic agents (e.g., live attenuated viral antigens, therapeutic proteins, etc.) and a lipid component. The lipid component may comprise or consist of different types of lipid or lipids as described herein. In some embodiments the therapeutic agents are thermolabile. The present disclosure also provides methods for preparing compositions, including the aforementioned compositions (e.g., melt methods and spray injection methods among others).
-
公开(公告)号：US20170349634A1
公开(公告)日：2017-12-07
申请号：US15683355
申请日：2017-08-22
Applicant: Variation Biotechnologies Inc.
Inventor： David E. Anderson , Anne-Catherine Fluckiger
IPC: C07K14/005 , A61K39/245 , A61K39/00
Abstract: The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).
-
公开(公告)号：US09833505B1
公开(公告)日：2017-12-05
申请号：US15642950
申请日：2017-07-06
Applicant: Variation Biotechnologies Inc.
Inventor： David E. Anderson , Anne-Catherine Fluckiger
CPC classification number: A61K39/12 , A61K2039/5256 , A61K2039/5258 , A61K2039/55505 , A61K2039/57 , A61K2039/575 , A61K2039/70 , C07K14/005 , C07K2319/40 , C12N7/00 , C12N2740/13022 , C12N2740/13023 , C12N2740/13034 , C12N2770/24122 , C12N2770/24123 , C12N2770/24134 , Y02A50/392
Abstract: The present disclosure provides compositions and methods useful for preventing and treating Zika virus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more Zika epitopes, such as, for example, from Zika envelope glycoprotein E and the Zika structural protein NS1 including variants thereof.
-
公开(公告)号：US20140370041A1
公开(公告)日：2014-12-18
申请号：US14161842
申请日：2014-01-23
Applicant: Variation Biotechnologies, Inc.
Inventor： Francisco Diaz-Mitoma , Andrei Ogrel , Jose V. Torres , David E. Anderson
IPC: A61K39/145 , C12N7/00 , C07K7/08 , A61K39/39 , C07K14/00
CPC classification number: A61K39/145 , A61K38/162 , A61K39/00 , A61K39/12 , A61K39/39 , A61K2039/542 , A61K2039/55505 , A61K2039/55511 , A61K2039/55555 , A61K2039/55561 , A61K2039/55572 , A61K2039/6018 , C07K7/08 , C07K14/00 , C07K14/005 , C12N7/00 , C12N2760/16122 , C12N2760/16134 , C12N2760/16171 , C12N2760/16222 , C12N2760/16234 , C12N2760/16271
Abstract: The present application provides compositions and methods useful for treating influenza. As described herein, the compositions and methods are based on the development of peptides and peptide combinations which exhibit immunogenic properties against influenza. In some embodiments, the peptide combinations induce a protective response against multiple strains of influenza, e.g., seasonal strains of influenza or even the new pandemic influenza A (H1N1) virus of swine origin.
Abstract translation: 本申请提供了可用于治疗流感的组合物和方法。 如本文所述，组合物和方法基于显示针对流感的免疫原性的肽和肽组合的开发。 在一些实施方案中，肽组合诱导针对多种流感病毒株的保护性应答，例如季节性流感病毒株，甚至猪来源的新的大流行性流感A（H1N1）流感病毒。
-
公开(公告)号：US12128100B2
公开(公告)日：2024-10-29
申请号：US17293431
申请日：2019-11-13
Applicant: Variation Biotechnologies Inc.
Inventor： David Evander Anderson , Tanvir Ahmed
CPC classification number: A61K39/292 , A61K45/06 , A61P31/20 , A61P37/04 , A61K2039/545 , A61K2039/55505 , A61K2039/57
Abstract: The present disclosure provides compositions and methods useful for inducing a The cell response in a subject suffering from Hepatitis B. As described herein, the compositions of the disclosure comprise HBsAg having S, Pre-S1 and Pre-S2 proteins and an aluminum phosphate adjuvant. In a preferred embodiment, the immunogenic composition comprises at least 20 μg/ml of HBsAg antigen and the amount of non-adsorbed antigen is at least 30%.
-
Patent Agency Ranking
公开(公告)号：US20230272013A1
公开(公告)日：2023-08-31
申请号：US17670052
申请日：2022-02-11
Applicant: Variation Biotechnologies Inc.
Inventor： David E. Anderson , Anne-Catherine Fluckiger
IPC: C07K14/005 , A61K39/245
CPC classification number: C07K14/005 , A61K39/245 , A61K2039/70
Abstract: The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).
-
公开(公告)号：US20230079703A1
公开(公告)日：2023-03-16
申请号：US17293431
申请日：2019-11-13
Applicant: Variation Biotechnologies Inc.
Inventor： David Evander ANDERSON , Tanvir AHMED
Abstract: The present disclosure provides compositions and methods useful for inducing a The cell response in a subject suffering from Hepatitis B. As described herein, the compositions of the disclosure comprise HBsAg having S, Pre-S1 and Pre-S2 proteins and an aluminum phosphate adjuvant. In a preferred embodiment, the immunogenic composition comprises at least 20 μg/ml of HBsAg antigen and the amount of non-adsorbed antigen is at least 30%.
-
公开(公告)号：US20230022956A1
公开(公告)日：2023-01-26
申请号：US17940117
申请日：2022-09-08
Inventor： Kirsten SCHNEIDER-OHRUM , David Evander ANDERSON
IPC: A61K39/245 , A61K9/127 , A61K39/21 , A61K39/39
Abstract: The present disclosure provides compositions and methods useful for treating Glioblastoma Multiforme (GBM) which comprise virus-like particles (VLPs) comprising murine leukemia virus (MLV) core proteins and the human cytomegalovirus epitopes, gB and pp65, formulated with an adjuvant comprising a saponin and a TLR4 agonist.
-
公开(公告)号：US10105440B2
公开(公告)日：2018-10-23
申请号：US15348881
申请日：2016-11-10
Applicant: VARIATION BIOTECHNOLOGIES INC.
Inventor： Maura Ellen Campbell
IPC: A61K39/39 , A61K39/00 , C07H13/04 , C07H13/06 , A61K39/145 , A61K39/112 , A61K39/02 , A61K39/21 , A61K39/29 , C07H15/12 , A61K39/12 , A61K9/00 , A61K9/127 , A61K9/19
Abstract: In one aspect, the present disclosure provides compounds of formulae I and II. In another aspect, a compound of formula I or II is formulated into compositions with an antigen, optionally with a vesicle. In some embodiments, compositions are administered intramuscularly.
-
公开(公告)号：US09603920B2
公开(公告)日：2017-03-28
申请号：US14161842
申请日：2014-01-23
Applicant: Variation Biotechnologies, Inc.
Inventor： Francisco Diaz-Mitoma , Andrei Ogrel , Jose V. Torres , David E. Anderson
IPC: A61K39/145 , A61K39/12 , C07K7/08 , C07K14/00 , C12N7/00 , A61K39/39 , C07K14/005 , A61K38/16 , A61K39/00
CPC classification number: A61K39/145 , A61K38/162 , A61K39/00 , A61K39/12 , A61K39/39 , A61K2039/542 , A61K2039/55505 , A61K2039/55511 , A61K2039/55555 , A61K2039/55561 , A61K2039/55572 , A61K2039/6018 , C07K7/08 , C07K14/00 , C07K14/005 , C12N7/00 , C12N2760/16122 , C12N2760/16134 , C12N2760/16171 , C12N2760/16222 , C12N2760/16234 , C12N2760/16271
Abstract: The present application provides compositions and methods useful for treating influenza. As described herein, the compositions and methods are based on the development of peptides and peptide combinations which exhibit immunogenic properties against influenza. In some embodiments, the peptide combinations induce a protective response against multiple strains of influenza, e.g., seasonal strains of influenza or even the new pandemic influenza A (H1N1) virus of swine origin.
-
-
-
-
-
-
-
-
-
Search Results
33
records
(took 0.019 seconds)
